Molnupiravir for oral solution preparation

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org

1 post / 0 new
Lynn Mitterer
Lynn Mitterer's picture
Offline
Last seen: 1 week 23 hours ago
Joined: 01/10/2023 - 08:47
Molnupiravir for oral solution preparation

Good morning,

Does anyone have a process for preparing this product and what precautions you have taken? Have you or would you allow this to prepared bedside? It has a short stability of 1 hour per the manufacturer. They do provide instructions for preparing the product (from their fact sheet for HCPs):

Administration via Nasogastric (NG) or Orogastric (OG) Tube (12F or Larger)
1. Open four (4) capsules and transfer contents into a clean container with a lid.
2. Add 40 mL of water to the container.
3. Put the lid on the container and shake to mix the capsule contents and water thoroughly
for 3 minutes.
o NOTE: Capsule contents may not dissolve completely.
o The prepared mixture may have visible undissolved particulates and are
acceptable for administration.
4. Flush NG/OG tube with 5 mL of water prior to administration.
5. Using a catheter tip syringe, draw up the entire contents from the container and
administer immediately through the NG/OG tube (12F or larger). Do not keep the
mixture for future use.
6. If any portion of the capsule contents are left in the container, add 10 mL of water to the container, mix, and using the same syringe draw up the entire contents of the container and administer through the NG/OG (12F or larger). Repeat as needed until no capsule contents are left in the container or syringe.
7. Flush the NG/OG tube with 5 mL of water twice (10 mL total) after administration of the mixture.

Risk Summary
Based on animal data, LAGEVRIO may cause fetal harm when administered to pregnant
individuals. There are no available human data on the use of LAGEVRIO in pregnant individuals
to evaluate the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes;
therefore, LAGEVRIO is not recommended during pregnancy.